Petersen Kyle, Riddle Mark S, Jones Lindsay E, Furtek Kari J, Christensen Anne R, Tasker Sybil A, Hale Braden R
National Naval Medical Center, Bethesda, MD, USA.
AIDS. 2005 Oct 14;19(15):1700-2. doi: 10.1097/01.aids.0000186826.60983.85.
We retrospectively reviewed 134 patients to evaluate atazanavir-related bilirubin elevation as an adherence marker. Using a 2 log reduction or undetectable viral load as a marker for suppression, the median bilirubin increase at first follow-up was 1.3 (0.7-2.2), versus 0.2 (-0.05-0.65) for those not suppressed. An increase in bilirubin of more than 0.4 mg/dl correctly classified 81% of patients as having successful treatment response (sensitivity 87%, specificity 63%), suggesting that bilirubin is a good adherence marker.
我们回顾性分析了134例患者，以评估阿扎那韦相关的胆红素升高作为依从性标志物的情况。以病毒载量降低2个对数或检测不到作为病毒抑制的标志物，首次随访时胆红素升高的中位数为1.3（0.7 - 2.2），而未被抑制的患者为0.2（-0.05 - 0.65）。胆红素升高超过0.4mg/dl可正确将81%的患者分类为治疗反应成功（敏感性87%，特异性63%），这表明胆红素是一个良好的依从性标志物。
